S
treptococcus imeumoniae is the most frequent causative agent of bacterial pneumonia and otitis media, one of the major causes of meningitis, and a primary source of death worldwide (1) (2) (3) . Among infants and young children, acute otitis media (AOM) is the most common disease caused by this pathogen (4--6) . It has been estimated that approximately three fourths of all children experience at least one episode of AOM and that >50% of these cases are caused by S. pneumoniae. S. pneumoniae, therefore, accounts for >106 cases of middle ear infection in the United States alone in children under 2 yr of age (1) . In addition, S. pneumoniae continues to be a major respiratory tract pathogen of adults, especially the elderly, and is responsible for '~40,000 deaths per year among adults in the United States (7) . The increasing frequency worldwide of antibiotic-resistant S. pneumoniae, as well as the morbidity and mortality associated with pneumococcal disease, argue for prophylactic vaccination as a means to protect against infection.
The pneumococcal vaccine currently available is a polyvalent vaccine composed of unconjugated, purified, pneumo-2277 coccal capsular polysaccharides. Whereas this vaccine has been shown to be protective in adults (8, 9) , it is of limited use in infants and children since the latter populations are poor responders to polysaccharide antigens and generally fail to generate protective antibodies to isolated polysaccharides (10) (11) (12) (13) . Protein antigens, in contrast to polysaccharides, have the advantage that they are immunogenic in infants as well as adults. The need for a pneumococcal vaccine that is effective in young children and infants has prompted studies to identify protein antigens of the pneumococcus that are able to elicit protective immune responses. The pneumococcal sur-exhibits considerable cross-reactivity and is capable of eliciting cross-protection against strains of different PspA and capsular types (18, 19 , and Briles, D. E., and L. S. McDaniel, manuscript in preparation). Furthermore, mAbs to PspA provide passive protection in mice against fatal pneumococcal infection (16, 18, 20) . In addition, it has been shown that X-linked immunodeficient (Xid) mice, which like young children are unable to mount immune responses to polysaccharide vaccines (21) , produce antibodies to PspA (22) . The anti-PspA antibodies are able to protect against death even in the absence of other antipneumococcal antibodies. Taken together, these studies suggest that the PspA protein may be a good candidate antigen for incorporation into a pneumococcal vaccine.
Bacille Calmette-Gurrin (BCG), an attenuated strain of
Mycobacterium bovis, offers a number of advantages as a vaccine vehicle for delivering foreign antigens such as PspA. BCG is already the most widely administered live vaccine, having been given as an antituberculosis vaccine to >2.5 billion people worldwide (23) (24) . Because of its safety record, it is suitable for immunization of young children and infants. BCG is also relatively inexpensive to produce and has strong immunostimulatory properties that produce long-lasting sensitization to mycobacterial antigens. Recently developed genetic systems for the expression of foreign antigens in mycobacteria (25) (26) (27) (28) have enabled the evaluation of rBCG as a vaccine delivery vehicle. Subsequent studies have demonstrated that rBCG can elicit antigen-specific systemic antibody responses after parenteral or mucosal (intranasal) immunization and that these antibodies are protective (29, 30, 30a) . For example, humoral antibodies to the outer-surface protein A (OspA) ofBorrelia lmrgdo~feri dicited by a rBCG vaccine have been shown to be protective against challenge with/g burgdorferi in a mouse model for Lyme borreliosis (29, 30) . Also, BCG expressing gp63 from Leishmania major have been shown to induce strong protective responses in a mouse model for Leishmaniasis (30) and antibodies to tetanus toxin fragment C expressed in rBCG have been shown to protect against challenge with tetanus toxin (31) . Thus, rBCG vaccines expressing PspA (rBCG-PspA) were constructed to test their efficacy as candidate vaccines against pneumococcal disease. In this paper we report on protective humoral responses elicited by such rBCG-PspA vaccines in the mouse model for pneumococcal disease.
Materials and Methods

Construction of BCG/Escherichia coli Shuttle Expression Vectors for
Expression ofpspA. Plasmid vectors pMV206 and pMV261 (25) are the parental plasmids for all the plasmid constructs described below. Plasmid pMV206 is composed of DNA cassettes encoding Kanamycin resistance (Kan), an E. coil origin of replication (Erep), a mycobacterial plasmid replicon derived from plasmid pAL5000 (Mrep), and a multiple cloning site (MCS) all assembled into a mycobacterial-E, coli shuttle vector, pMV261 is similar to pMV206 but also includes the promotor, ribosomal binding site (RBS), and initial six codons of the BCG heat shock protein 60 (hsp60) gene inserted between XbaI and BamHI sites of the multiple cloning site of plasmid pMV206. Plasmid pRB26 differs from pMV261 in that it contains only the BCG hsp60 promotor but not the hsp60 RBS nor any of the hsp60 coding sequence (29) . Plasmid expressionAecretion vector p2619s was constructed by inserting a PCRderived DNA segment encoding the Myocobacterium tuberculosis 19- kD (Mtb19) RBS and 5' lipoprotein signal peptide downstream from the hsp60 promotor of phsmid pRB26. For two of the plasmids encoding papA, pMV261-pspA33 and p2619-pst2A33, a pspA gene segment encoding the NHz-terminal region of the PspA protein, spanning amino acids +4 to +299, was amplified by PCR from DNA derived from S. traeuraoniae strain Rxl (32) and cloned between the BamHI and SalI sites in the MCS of plasmids pMV261 and p2619 to yield plasmids pMV261-pspA33 and p2619-pspA33, respectively, (see Fig. 1 ); 5' BamHI and 3' SalI restriction sites were incorporated into the primers for subcloning. The predicted size of the PspA-derived peptide encoded by these plasmids, 33 kD, is larger than that encoded by the originalpspA truncation mutation as reported by Talkington et al. (pJY2008) (33) . For plasmid pRB26-pspA33, the cloned pspA fragment encodes a protein that extends from the first residue of the PapA leader sequence (-31) through residue +299 (see Fig. 1 ). A PCR-amplified BamHI-SallpspA gene segment (pspA69) encoding the full-length 69-kD PspA protein without signal peptide was cloned into another vector, the hsp60-/acZ fusion vector pSL26 which is a derivative of plasmid pMV261.
pSL26 incorporates the 5' region ofE. coli lacZ (encoding the first 71 codons) upstream of the first six hsp60 codons of pMV261. The resulting vector was termed pSL26-pspA69.
Growth of BCG and Transformation of Shuttle Plasmids into BCG. All liquid cultures ofBCG substrain Pasteur 1173P2 were grown at 37~ in stationary tissue culture flasks (25 cm 2 with 5-10 ml or 75 cm z with 15-25 ml) or roller bottles (490 cm 2 with 100-200 ml or 1,700 cm 2 with 200-500 ml) using Dubos (Difco Laboratories, Detroit, MI) media supplemented with 1/10th volume of AD enrichment consisting of 5% BSA fraction V (Sigma Chemical Co., St. Louis, MO), 2% dextrose, and 0.85% sodium chloride. Liquid culture media included 0.02% Tween 80 (T80) to prevent clumping of BCG cells. BCG colonies were grown at 37~ on Middlebrook 7H10 agar media (Difco Laboratories) supplemented with 1/10th volume of AD enrichment. For transformation, BCG cultures were grown to densities of ~107 CFU/ml, sedimented at 4,000g, and washed twice by resuspension and centrifugation (4,000 g) in 10% glycerol at 4~ and finally resuspended in 1/20th of the original culture volume of cold 10% glycerol. Then 200/~1 of the cold BCG suspension was mixed with plasmid DNA (50-500 ng) in a prechilled 0.2-cm electroporation cuvette and transformed using the Biorad Gene Pulser electroporator (both from Bio-Rad Laboratories, Richmond, CA) at 2.5 kV, 25 mr, and 1,000 W. After electroporation, 50/~1 5 x Dubos media was added to the BCG-DNA suspension, and the mixture was incubated at 37~ for I h before plating on Middlebrook 7H10 plates supplemented with AD enrichment and kanamycin (15/~g/ml).
Analysis of pspA Expression in rBCG. BCG transformants were grown to mid-logarithmic phase in Dubos liquid media containing kanamycin (15/~g/ml). After washing the cells in PBS plus 0.05% T80, the cell suspension was concentrated 20-fold in RIPA buffer (1% NP-40, 0.5% Deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) to lyse the cells. Culture lysates were analyzed by SDS-PAGE and Western blot with the PspA-specific mAb Xi126 (15 Immunizations with rBCG Strains. rBCG cultures were grown in roller bottles to optical densities of ~1.2 A~0 U (=2 x 10 s CFU/ml), concentrated 20-fold by centrifugation at 4,000 g, and resuspended in I ml of 15% glycerol. The rBCG glycerol suspensions were gradually frozen at a rate of -1~ per minute, from 4~ to -40~ and then stored at -70~ until use. CFU were assayed by growing thawed material on Middlebrook 7H10 plates plus kanamycin at various dilutions.
4-6-wk-old female BALB/c and C3H/HeJ mice (The Jackson Laboratory, Bar Harbor, ME) were immunized by the intraperitoneal route with 106 rBCG CFU in 100/~1 of PBS-T80.
Anti-PspA Response oflmmunizedMicc Sera were collected from the tail veins of immunized mice at 4-wk intervals and pooled for each group to monitor antibody responses by ELISAs with purified PspA protein (provided by Dr. P. H. McVerry. ELISA plates (Iratoulon 4; Dynatech Laboratories, Inc., Chantilly, VA) were coated with 50/~1 of PspA protein (0.1/~g/ml) in 0.1M carbonate buffer, pH 9.6, and incubated for 2-4 h at room temperature or overnight at 4~ The antigen solution was removed and plates were incubated with blocking solution (0.5% BSA and 0.5% nonfat dry milk in H20) for 1 h at room temperature. Twofold serial dilutions of serum starting at 1:200 were made in blocking solution and 50 /~1 of each dilution was added to duplicate wells of the antigencoated plate. After an incubation at room temperature for 1 h, the coated plates were washed with PBS plus 0.1% Tween-20 (T20) and incubated with 50 /~1 of a 1:4,000 PBS-T20 dilution of peroxidase-conjugated goat anti-mouse IgG (Kirkegaard & Perry Laboratories, Gaithersburg, MD) secondary antibody for 1 h at room temperature. Color was developed with ABTS substrate reagent (Kirkegaard & Perry Laboratories) and measured by absorbance at 405 nm on a Dynatech ELISA reader. Endpoint titers were defined as the highest dilution at which the Aos values were twice the values for preimmune sera diluted 1:200 in blocking solution.
Mouse Protection Experiments in rBCG-Pst~A Immunized Mice. BALB/c and C3H/HeJ mice immunized with rBCG-PspA vaccine strains were challenged intraperitoneally with 104 CFU (100 x LDs0) of the highly lethal S. pneumoniae strain WU2 (34) . Immediately after challenge, samples of the S. Imeumoniae challenge inoculum were plated on trypticase soy blood agar plates to determine the CFU and verify the challenge dose. Deaths were recorded at 24-h intervals. Most deaths occurred between days 2 and 4 after challenge, however the mice were observed for a total of 10-12 d as indicated.
Passive Protection Experiments with Antisera from rBCG-PspA Immunized Mice. Anti-PspA antisera collected from mice vaccinated with rBCG containing p2619-pspA33 was administered passively in 0.1-ml volumes into CBA/N mice by the intraperitoneal route at a 1:40 dilution on days 0, 2, and 3. Mice were challenged by the intravenous route on day 0 with 500 CFU of each of five highly virulent strains of S. pneumoniae (35) , in a total volume of 0. 
Results
Expression and Localization of PspA in rBCG.
Previously we have shown that rBCG can elicit both humoral and eellular immune responses to foreign antigens expressed in the cytoplasm of rBCG (25, 31) . More recently, we reported on the development of rBCG expression vectors that allow for the export or secretion of foreign antigens from rBCG by fusing the recombinant proteins to the Mtb19 lipoprotein signal peptide (29) . In the case of at least one antigen, the OspA of/~ burgdorferi, secretion and surface expression resulted in much stronger antigen-specific and protective humoral and cellular responses than was possible with cytoplasmic expression in rBCG.
A In all three vectors, expression of the pspA33 gene segment was driven by the BCG hsp60 promoter on a multi-copy extra chromosomal plasmid vector (Fig. 1) . In addition, a gene segment encoding the full-length 69-kD PspA protein, with or without the 5' region encoding the PspA signal peptide, was cloned into a variety of BCG expression vectors that all utilized the BCG ~p60 promoter (Fig. 2 legend) .
Expression of PspA gene segments from all of the rBCG expression vectors was confirmed by SDS-PAGE and Western blot analysis of whole-cell BCG lysates. The highest level of expression was seen in rBCG transformed with the cytoplasmic expression vector pMV261-pspA33 encoding the NH2-terminal protective PspA33 domain without signal peptide. Cytophsmically expressed PspA33 (C-PspA) in rBCGpMV261-pspA33 accounted for "~15% of the total BCG protein, and the amount produced was two-to fivefold greater than that seen with rBCG carrying plasmids pP, B26-pspA33 or p2619-pspA33 encoding either PspA33 with the natural pneumococcal signal peptide (S-PspA) or the Mtb19 lipoprorein signal peptide (L-PspA), respectively (Fig. 2) .
Expression of the full-length 69-kD PspA protein was seen only in lysates of BCG strains transformed with the pSL26-pspA69 plasmid (Fig. 2) . Whereas rBCG-pSL26-pspA69 expressed low levels of a full-length Hsp60-LacZ-PspA fusion protein without signal peptide, this rBCG strain was dif~cult to maintain in culture and was therefore not pursued further. The inability to obtain stable rBCG strains ex- pressing the full-length PspA protein with its natural COOHterminal anchor domain would suggest that expression of the pneumococcal repetitive anchor domain is deleterious to BCG. rBCG expressing all the different PspA33 constructs were fractionated by the Triton X-114 detergent phase partitioning method to determine the cellular location of the different recombinant PspA33 polypeptides (29) (data not shown). Only the chimeric PspA lipoprotein expressed from vector p2619-psM33 was localized to the BCG membrane. The PspA lipoprotein expressed from the p2619 vector was also accessible to surface labeling with anti-PspA antibody as determined by flow cytometry studies, which is consistent with previous studies utilizing the same vector to express OspA from R burgdorferi as a recombinant surface antigen in BCG (29) . Whereas most of the PspA protein expressed from vectors pMV261-pspA33 and pRB26-pspA33 was found in the cytoplasmic fractions, small amounts were also found in the media suggesting limited transport or secretion of the PspA protein with or without the signal peptide (data not shown). This unexpected finding, which cannot be explained presently, could not be accounted for by autolysis of the rBCG since hsp60, a cytoplasmic heat shock protein which is produced in abundance by BCG, was not detected in the same media fractions.
Immunization with rBCG Expressing PsFA as a Secreted Protein or Chimeric Lipoprotein Elicits Protective Humeral Immunity in both BALB/c and C3 H Mice. C3H and BALB/c mice were immunized intraperitoneally with 106 CFU of the rBCGPspA vaccines described above and evaluated for PspA-specific IgG responses. Both strains of mice mounted strong antibody responses to PspA regardless of whether PspA was expressed in the cytoplasm, exported to the surface of BCG, or secreted (Fig. 3) . In all cases, reciprocal ELISA titers to PspA ranged from 103 to 104 after a single immunization and increased 10-fold (104 tO l0 s reciprocal titers) after a booster immunization at ,v17 wk postprimary immunization. However, only the rBCG vaccines expressing PspA as a secreted protein (pRB26-pspA) or as a chimeric lipoprotein (pMV2619-pspA) elicited protective immunity against pneumococcal challenge with 100 LDs0 of virulent pneumococci (strain WU2) in both C3H and BALB/c mice (Fig. 3) . The level of protection against pneumococcal challenge ranged from 50% for C3H mice to as high as 90% for BALB/c. In this particular experiment, the secreted form of PspA afforded a slightly higher level of protection than the lipidated PspA. It is surprising that whereas comparable ELISA end-point titers to PspA were observed in animals immunized with the nonsecreted, cytoplasmic rBCG containing the pMV261-pspA clone, only modest protection against pneumococcal challenge was seen, and only in the CH3 strain of mice. Immunization with rBCG expressing the unrelated OspA antigen as a lipoprotein did not protect against pneumococcal challenge in either C3H or BALB/c mice.
In a subsequent experiment, C3H and BALB/c mice were In a subsequent experiment, C3H and BALB/c mice were immunized intraperitoneally with 106 CFU of either rBCG expressing the secreted (S-PspA) or the lipidated (L-PspA) form of PspA, and were challenged with a lethal dose of virulent pneumococci to confirm the protective efficacy of these two rBCG vaccine strains. Once again, reciprocal titers to PspA ranged from 103 to 104 after a single immunization and increased 10-fold (104 to 105 reciprocal titers) after a booster immunization at 17 wk. When the mice were challenged with 100x LDs0 virulent pneumococci, 80% of the C3H and 100% of the BALB/c mice receiving either of the rBCGPspA vaccine strains survived (Fig. 4) . A small percentage of the control mice survived presumably due to nonspecific immunity to S. pneumoniae.
I~sive Transfer of Antibody from rBCC,-PspA-immunized Mice Protects CBA/N Mice from Lethal Challenge with Diverse Strains
Discussion
Previous studies have shown that antibody raised against purified PspA protein, a surface antigen present on all S. pneumoniae clinical isolates (17) , protects against fatal S. pneumoniae infection in mice (16, 18, 20, 22) . In this report, we demonstrate that a single inoculation with a live BCG bacterial vaccine expressing PspA as a secreted mature protein or a chimeric exported lipoprotein (rBCG-PspA), followed by a booster at 17 wk, results in a protective humoral antibody response against virulent S. pneumoniae. These results lend further support to a role for anti-PspA antibodies in protecting against pneumococcal infection and demonstrate that BCG is a powerful vaccine vehicle for eliciting such a protective response. BCG, an attenuated bovine tubercle bacillus used as a vaccine for tuberculosis, offers considerable advantages as a safe, live vaccine vehicle for the expression and delivery of protective recombinant antigens. It is the most widely used vaccine in the world with a low incidence of serious complications, it can be given at birth, and is unaffected by maternal antibodies (23, 24, 37) . Furthermore, given that BCG can accommodate large pieces of foreign DNA, it is also possible to develop rBCG which allow for the simultaneous expression of multiple protective antigens derived from different pathogens (25, 27, 28, 38, 39) . All of these factors are particularly important to consider in the development of a pneumococcal vaccine that is targeted predominantly to infants.
In addition, it is important to consider the potential side effects associated with a live bacterial vaccine vector such as BCG. The most frequent adverse reaction to BCG is suppurative lymphadenitis (40) . However, it has clearly been shown in studies conducted with BCG strains used for ira- mice (29, 30a) . To evaluate the potential for rBCG vaccines to elicit a humoral immune response to PspA, the NH2-terminal half of the PspA protein was expressed in BCG as a secreted protein or as a chimeric membrane-associated lipoprotein by fusion to a 5' DNA sequence encoding the Mtb19 lipoprotein signal peptide; the NH2-terminal portion of PspA was expressed as a cytoplasmic protein as well for comparative purposes. The NH2-terminal region of PspA was cloned into BCG since previous studies had demonstrated that antibodies targeted to epitopes within this half of the protein are protective (33) . Furthermore, expression of the complete PspA antigen in rBCG was toxic to the bacteria unless the PspA signal peptide was deleted and replaced with the NH2-terminal 75 amino acids of the/3-galactosidase protein, for reasons that are unclear.
C3H Antibody Responses
Antibody responses against PspA were observed in BALB/c and C3H/HeJ mice with all rBCG vaccines. Whereas peak antibody ELISA titers elicited by rBCG expressing PspA with or without secretion signal peptides did not differ markedly, protective responses were observed only in mice immunized with rBCG expressing PspA with its native signal peptide or as a fusion with the Mtb19 lipoprotein signal peptide. In contrast, prior studies had shown that export of a different foreign antigen,/~ burgdo~eri OspA, from the rBCG cytosol, seemed to be required for maximum levels of both total antibody and protective immunity against challenge (29) . One possible explanation for this difference is that, unlike OspA, some chimeric PspA is transported across the membrane even in the absence of a signal peptide, by some as yet unexplained mechanism. This possibility is suggested by limited fraction- ation studies using the various PspA recombinants (data not shown). The cytoplasmic form of PspA might not be conformationally correct to induce a protective response even in its "transported" form. Conversely, PspA protein expressed with its natural signal peptide or as a chimeric lipoprotein anchored to the BCG membrane both induce protective responses perhaps since, in both cases, protective epitopes are expressed in the appropriate conformation. Another possibility for the difference in terms of protective responses, is that the cytoplasmically expressed PspA may be processed by the host once the rBCG enters the endosome, and the processed form of PspA fails to elicit a protective antibody response. These possible explanations require further investigation beyond the scope of this study. In any case, it is clear that the antibody response to a cloned antigen in rBCG may vary with the particular recombinant protein and how it is expressed. This will be an important consideration in the development of multivalent rBCG vaccines. The pspA gene fragment, cloned and expressed in the rBCGPspA vaccines, was derived from the Rxl strain ofS. pneumoniae which expresses type 25 PspA (36), one of over 31 PspA serotypes as classified by mAb reactivity (17, 42) . Whereas PspA displays interstrain variation in its size and in the expression of individual antibody-reactive epitopes (17, 43) , there is a high degree of cross-reactivity among the PspA serotypes (18, 19 , and Briles, D. E., and L. S. McDaniel, manuscript in preparation). Consistent with this observation, we have demonstrated that passive administration of antisera from mice immunized with a rBCG-PspA vaccine protects against lethal challenge with S. pneumoniae strains that express heterologous PspA serotypes. We have also shown that the rBCGPspA vaccine elicits protection against pneumococci of more than one capsular serotype, which again is consistent with previous immunogenicity studies using recombinant PspA proteins (18, 19) . Whereas the rBCG-PspA vaccines were highly protective against S. pneumoniae challenge, absolute protection was not always observed. The lack of protection in some mice was not a function of their failure to respond to the rBCG-PspA vaccine; all mice given the rBCG-PspA vaccine mounted strong antigen-specific responses (data not shown).
It should be noted that CBA/N mice were used in the passive protection studies rather than BALB/c or C3H mice, because they have become a standard model for passive protection with antibody to pneumococcal antigens (34, 35, (44) (45) (46) . CBA/N (Xid) mice are more susceptible to most pneumococcal infections than BALB/c and C3H mice as well as most other strains of mice (47) . Thus, protection of Xid mice against pneumococcal challenge is a particularly stringent test of protective efficacy of antipnenmococcal antibodies. Furthermore, as another measure of stringency in the passive protection assay, Xid mice were challenged intravenously rather than intraperitoneally. Whereas in general strains that are virulent intravenously are also virulent when inoculated intraperitoneally (35, 48) , death occurs a day or two earlier in mice challenged by the intravenous route. Another reason for choosing to do passive protection studies in Xid mice was that whereas most strains of mice including BALB/c and C3H/HeJ have antiphosphocholine antibodies in their serum, which is protective against challenge with low inocula of many pneumococcal strains (35) , antibodies against phosphocholine and most carbohydrates are absent in Xid mice (35) . Therefore, Xid mice provide the best opportunity to assay for the protective effects of spedfic, passively administered antibodies in the absence of potentially protective, endogenous antibodies. Nonetheless, recent studies in one of the investigators' laboratory have demonstrated that the anti-PspA antibodies protect against pneumococcal infection regardless of the route of challenge and independent of the Xid status of the mouse (Benton, K., and D. Briles, manuscript in preparation).
Overall, the mouse model for pneumococcal disease is useful in terms of identifying and characterizing protective, systemic antibody responses that clear disseminated infections. However, initial colonization by S. Imeurnoniae occurs along mucosal surfaces in the upper respiratory tract, a site where secretory antibodies of the IgA subclass may play an important role in prevention of mucosal surface colonization by pathogenic organisms (49) (50) (51) (52) . Thus, it may be important to stimulate immune responses at mucosal surfaces to block colonization and to evaluate the protective efhcacy of such responses in an appropriate challenge model. Recently, we demonstrated that mucosal immunization with a live rBCG vaccine expressing the OspA antigen results in a prolonged secretory IgA response that is disseminated throughout the mucosal immune system, including the upper respiratory tract, as well as a prolonged and protective systemic immune response against a target pathogen (30). A similar approach may now be taken with rBCG expressing PspA to determine if mucosal delivery of such a vaccine results in protection against pneumococcal infection and disease.
